Carl has served on the board of directors of Electra Therapeutics since March 2019. He is a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors LLC, an investment firm, where he has served since January 1998. He currently serves on the boards of directors of Compass Therapeutics (since September 2015), BlossomHill Therapeutics (since February 2021), Scribe Therapeutics (since March 2021), and Lomond Therapeutics Holdings (since August 2024), and several other privately held companies.
Carl previously served on the boards of directors of Adicet Bio (August 2015 to April 2025), ArriVent Biopharma (December 2022 to June 2025), Gemini Therapeutics, which merged with Disc Medicine (April 2016 to December 2022), Keros Therapeutics (March 2020 to March 2026), Kinnate Biopharma (December 2019 to April 2024), MBX Biosciences (July 2020 to June 2025), ORIC Pharmaceuticals (November 2015 to November 2021), Terns Pharmaceuticals (October 2018 to February 2025), and Theseus Pharmaceuticals (June 2018 to February 2024).
Carl received a B.A. in Chemistry from Harvard College and a Ph.D. in molecular biology from the Massachusetts Institute of Technology, and he was a Fellow at The Rockefeller University.
What is Carl L. Gordon's net worth?
The estimated net worth of Carl L. Gordon is at least $59.22 million as of September 21st, 2026. Dr. Gordon owns 5,126,891 shares of Electra Therapeutics stock worth more than $59,215,591 as of September 28th. This net worth estimate does not reflect any other assets that Dr. Gordon may own. Learn More about Carl L. Gordon's net worth.
How do I contact Carl L. Gordon?
Has Carl L. Gordon been buying or selling shares of Electra Therapeutics?
Over the course of the past ninety days, Carl L. Gordon has bought $19,999,995.00 of Electra Therapeutics stock. Most recently, on Monday, September 21st, Carl L. Gordon bought 1,333,333 shares of Electra Therapeutics stock. The stock was acquired at an average cost of $15.00 per share, with a total value of $19,999,995.00. Following the completion of the transaction, the director now directly owns 5,126,891 shares of the company's stock, valued at $76,903,365. Learn More on Carl L. Gordon's trading history.
Are insiders buying or selling shares of Electra Therapeutics?
During the last year, Electra Therapeutics insiders bought shares 2 times. They purchased a total of 2,666,666 shares worth more than $39,999,990.00. The most recent insider tranaction occured on September, 21st when Director
Carl L. Gordon bought 1,333,333 shares worth more than $19,999,995.00.
Learn More about insider trades at Electra Therapeutics. Information on this page was last updated on 9/21/2026.
